Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + pegylated liposomal doxorubicin versus carboplatin + paclitaxel in platinum-sensitive recurrent ovarian cancer
ACTRN12609000436279Phase 2Completed
- Sponsor
- HeCOG
- Start
- Oct 1999
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer comparing Carboplatin + pegylated liposomal doxorubicin with Carboplatin + paclitaxel (2 arms). Primary endpoint: Response rate. Started Oct 1999; status: completed.
02
Drugs
carboplatindoxorubicinpaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ACTRN12609000436279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000436279.